Neglected Tropical Disease (NTD) Treatment Market To Reach $6.46 Billion by 2035

Neglected Tropical Disease (NTD) treatment market was valued at $3.61 billion in 2025 and is projected to reach $6.46 billion by 2035, growing at a CAGR of 6.0% during the forecast period (2026–2035). The increasing global burden of infectious and vector-borne diseases is a major macro driver supporting market growth. According to the World Health Organization (WHO), neglected tropical diseases affect more than 1 billion people globally, while nearly 1.495 billion people required interventions against NTDs in 2023. The growing prevalence of diseases such as dengue, schistosomiasis, leishmaniasis, and lymphatic filariasis is increasing the demand for advanced therapeutics, vaccines, and integrated disease management programs globally.

Browse the full report description of “Neglected Tropical Disease (NTD) Treatment Market Size, Share & Trends Analysis Report, By Disease Type (Lymphatic Filariasis, Onchocerciasis (River Blindness), Schistosomiasis, Soil-Transmitted Helminthiasis, Leishmaniasis, Chagas Disease, Human African Trypanosomiasis (Sleeping Sickness), Dengue & Arboviral Infections, Leprosy, Trachoma, Buruli Ulcer, Other Neglected Tropical Diseases), By Treatment Modality (Oral Therapies, Injectable Therapies, Topical Therapies, Vector-Control Integrated Therapeutics), By End User (Hospitals, Infectious Disease Clinics, Community Healthcare Centers, Public Health Programs, Research Institutes & Academic Centers), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/ntd-treatment-market

The rising incidence of dengue and arboviral infections is further strengthening market expansion. WHO reported that dengue transmission reached unprecedented levels globally, with more than 14.4 million cases reported in 2024. In addition, nearly half of the world’s population remains at risk of dengue infection due to rapid urbanization, climate change, and expansion of mosquito vectors. Growing government-supported elimination programs, increased pharmaceutical collaborations, and mass drug administration initiatives are accelerating treatment accessibility across endemic regions. Hospitals and public health programs continue to dominate the end-user segment due to large-scale treatment campaigns and government-supported infectious disease control programs.

Rising Investments in Vector-Borne Disease Control Supporting Market Growth

The disease type segment is witnessing substantial growth due to increasing prevalence of dengue, leishmaniasis, and soil-transmitted helminthiasis across Asia-Pacific, Africa, and Latin America. Oral therapies continue to dominate the treatment modality segment owing to their affordability, ease of administration, and large-scale usage in preventive chemotherapy programs. However, injectable therapies and vector-control integrated therapeutics are expected to witness strong growth due to rising investments in biologics, vaccines, and mosquito-control technologies. Public health programs and community healthcare centers remain key end users due to the expansion of WHO-backed eradication campaigns and government healthcare initiatives targeting underserved populations.

Key Leaders Transforming the Neglected Tropical Disease (NTD) Treatment Market

The key players in the neglected tropical disease (NTD) treatment market include Takeda Pharmaceutical Company Limited, Sanofi S.A., Bayer AG, GlaxoSmithKline plc, Knight Therapeutics Inc., among others. These companies are focusing on product innovation, partnerships, vaccine development, and geographical expansion strategies to strengthen their market presence.

• In April 2026, the Global Health Innovative Technology (GHIT) Fund announced an investment of approximately USD 8.5 million in malaria and neglected tropical disease (NTD) R&D projects in collaboration with partners including Medicines for Malaria Venture (MMV), GlaxoSmithKline (GSK), Eisai, DNDi, and Tanabe Pharma. The investment supports the development of new antimalarial and NTD therapeutics, highlighting increasing global collaboration and funding initiatives to strengthen infectious disease treatment pipelines.
• In January 2026, Sanofi announced strong financial performance for 2025, reporting double-digit quarterly sales growth and continued profitable growth expectations for 2026. The company highlighted expansion in its pharmaceutical and vaccine portfolio, along with plans to execute a €1 billion share buyback program in 2026 to strengthen shareholder value and support long-term growth strategies.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Disease Type
• Treatment Modality
• End User
• Competitive Landscape – Takeda Pharmaceutical Company Limited, Sanofi S.A., Bayer AG, GlaxoSmithKline plc, Knight Therapeutics Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Neglected Tropical Disease (NTD) Treatment Market Segmentation

By Disease Type

• Lymphatic Filariasis
• Onchocerciasis (River Blindness)
• Schistosomiasis
• Soil-Transmitted Helminthiasis
• Leishmaniasis
• Chagas Disease
• Human African Trypanosomiasis (Sleeping Sickness)
• Dengue & Arboviral Infections
• Leprosy
• Trachoma
• Buruli Ulcer
• Other Neglected Tropical Diseases

By Treatment Modality

• Oral Therapies
• Injectable Therapies
• Topical Therapies
• Vector-Control Integrated Therapeutics

By End User

• Hospitals
• Infectious Disease Clinics
• Community Healthcare Centers
• Public Health Programs
• Research Institutes & Academic Centers

Global Neglected Tropical Disease (NTD) Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ntd-treatment-market